Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 9, 1998

View Archived Issues

Company Profile: PolyMASC

CNS-5161 shows efficacy in phase I trial

Barr receives additional generic approval

Cell Therapeutics and City of Hope join forces for diabetes research

Second-generation CMV retinitis compound enters phase I/II

Beaufour Ipsen to market Tanabe ACE inhibitor

Serotone introduced in China

Ares-Serono's recombinant IFN-beta1a recommended for approval by CPMP for MS

MycoTox's antifungal program advances

New rationale elucidated for clinical evaluation of GW-506U in refractory hematologic malignancies

ADCON-L submitted to regulatory authorities

Report of ThromboSol efficacy presented at hematology congress

Genetronics' electroporation therapy further evaluated in French trial

Genentech licenses TPO to Pharmacia & Upjohn

Thrombin inhibitors reported by BMS

Novel diagnostic compositions reported by Amersham

New antiviral agents emerge from European research collaboration

HCAP discovered by Incyte; potential treatment for obesity

New therapeutic protein reported by Amgen

New phosphatase inhibitors from the University of Pittsburgh

Merck discloses novel D4 receptor ligands

Epix Medical's MRI contrast agent evaluated for breast cancer indications

NIH announces contemplation of licensing agreement for growth factors

NIH communication reports contemplation of licensing agreement

NIH seeks CRADA partners or licensees for 12-LO metabolite

New antiulcer agent now available in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...